Introduction

Zoryve (roflumilast) has become one of the most commercially important newer topical therapies in dermatology as its U.S. indications have expanded across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. Developed and commercialized by Arcutis Biotherapeutics, Zoryve is a nonsteroidal phosphodiesterase-4 (PDE4) inhibitor available in cream and foam formulations designed for different dermatologic needs.

The product's commercial trajectory changed materially between 2022 and 2026. Zoryve cream 0.3% was first approved in the United States in July 2022 for plaque psoriasis in patients aged 12 years and older. Zoryve foam 0.3% followed in December 2023 for seborrheic dermatitis in adults and children aged 9 years and older. In July 2024, the 0.15% cream formulation was approved for mild to moderate atopic dermatitis in patients aged 6 years and older. The atopic dermatitis indication was extended to children aged 2 to 5 years with the 0.05% cream in October 2025. In June 2026, the plaque psoriasis indication for the 0.3% cream was expanded to children as young as 2 years.

The expansion has been accompanied by substantial commercial growth. Arcutis reported Zoryve net product revenue of $372.1 million in 2025, up 123% from 2024. By the second quarter of 2026, quarterly Zoryve product revenue had reached $129.9 million, compared with $81.5 million in the same quarter of 2025. The company subsequently raised its 2026 full-year Zoryve net product sales guidance to $525 million-$540 million.

This makes Zoryve more than a single-product dermatology launch. It is developing into a franchise built around the same active ingredient but with multiple formulations, concentrations, age groups, and inflammatory skin diseases. For healthcare market participants, that strategy is particularly relevant because it demonstrates how formulation development and sequential label expansion can extend the commercial life of a topical medicine while opening additional patient segments.

What Is Zoryve?

Zoryve is the brand name for roflumilast, a selective PDE4 inhibitor developed for topical use in dermatology. PDE4 is an intracellular enzyme involved in the regulation of cyclic adenosine monophosphate (cAMP), a signaling molecule that influences inflammatory pathways. Inhibiting PDE4 increases intracellular cAMP and helps reduce the production and activity of inflammatory mediators involved in inflammatory skin diseases.

Roflumilast itself is not a new molecule. Oral roflumilast has been used for chronic obstructive pulmonary disease under a different product, Daliresp. Zoryve represents the topical application of roflumilast using formulations intended to deliver the drug directly to affected skin.

The U.S. Zoryve portfolio currently consists of cream and foam formulations:

• Zoryve cream 0.3% is approved for topical treatment of plaque psoriasis, including intertriginous areas, in adults and children aged 2 years and older.
• Zoryve cream 0.15% is approved for mild to moderate atopic dermatitis in adults and children aged 6 years and older.
• Zoryve cream 0.05% is approved for mild to moderate atopic dermatitis in children aged 2 to 5 years.
• Zoryve foam 0.3% is approved for seborrheic dermatitis in adults and children aged 9 years and older and for plaque psoriasis of the scalp and body in adults and children aged 12 years and older.

The cream formulations are applied once daily to affected areas. The foam was specifically developed to improve topical delivery to hair-bearing areas such as the scalp while avoiding some of the practical difficulties associated with conventional creams.

A topical alternative to corticosteroid-based treatment

One of Zoryve's most important commercial characteristics is that it is nonsteroidal. Topical corticosteroids remain a cornerstone of dermatologic treatment, but concerns about skin atrophy and other effects associated with prolonged or inappropriate corticosteroid exposure can influence treatment selection, particularly for chronic diseases and sensitive anatomical sites.

A nonsteroidal PDE4 inhibitor can therefore occupy a differentiated position in treatment algorithms. Zoryve's value proposition is not simply based on replacing corticosteroids. It is also connected to the ability to provide a once-daily treatment for chronic inflammatory diseases where patients may require repeated or long-term topical management.

This positioning is particularly relevant for areas such as the face, skin folds, genital or intertriginous regions, and scalp, where formulation characteristics and long-term tolerability can influence adherence.

Recent Developments and Trends

Expansion across three major dermatology indications

The defining trend for Zoryve has been sequential expansion into different inflammatory skin diseases.

The initial U.S. approval in July 2022 covered plaque psoriasis in patients aged 12 years and older. The pivotal DERMIS-1 and DERMIS-2 trials evaluated once-daily roflumilast cream 0.3% for eight weeks in patients with plaque psoriasis. Across the two Phase 3 studies, 881 participants were randomized, and roflumilast demonstrated significantly greater achievement of the primary Investigator Global Assessment success endpoint than vehicle.

The psoriasis indication was subsequently extended into younger children. In June 2026, FDA approved the 0.3% cream for plaque psoriasis in patients as young as 2 years. The expanded label covers plaque psoriasis, including intertriginous areas, and gives Zoryve one of the broader age ranges among nonsteroidal topical options for pediatric plaque psoriasis.

This is commercially relevant because pediatric dermatology has historically had fewer topical options suitable for long-term use. Expanding the age range does not automatically translate into proportional prescription growth, but it creates access to a population in which treatment choices may be constrained by age, tolerability, formulation, and concerns surrounding repeated corticosteroid exposure.

Zoryve foam expands treatment into seborrheic dermatitis

The December 2023 FDA approval of Zoryve foam 0.3% for seborrheic dermatitis opened a second disease market.

The foam formulation addresses a practical issue that is particularly relevant to scalp and hair-bearing skin. Conventional creams can be difficult to apply through hair, may leave residue, and can interfere with cosmetic routines. Zoryve foam was designed as a light formulation that can be distributed across the scalp without the same type of greasy residue associated with some traditional topical products.

The Phase 3 STRATUM trial provided the clinical basis for the seborrheic dermatitis approval. In the published study, 79.5% of patients receiving roflumilast foam achieved the primary Investigator Global Assessment success endpoint at week 8, compared with 58.0% receiving vehicle. Treatment effects were also observed earlier in the study, including at weeks 2 and 4.

The commercial relevance extends beyond the efficacy results. Seborrheic dermatitis is common, chronic, and frequently managed with repeated topical treatment. A once-daily nonsteroidal foam therefore gives Arcutis access to a population with a different treatment pattern from plaque psoriasis.

Foam formulation expands into scalp and body psoriasis

In May 2025, FDA expanded Zoryve foam 0.3% to include plaque psoriasis of the scalp and body in adults and pediatric patients aged 12 years and older.

The ARRECTOR phase 3 trial evaluated the foam in patients with scalp and body psoriasis. The study was designed around a practical unmet need: treating psoriasis on the scalp and other hair-bearing areas without the application challenges associated with some cream or ointment formulations.

This created a complementary relationship between the cream and foam versions of Zoryve. The cream can address plaque psoriasis across the body, including intertriginous areas, while the foam provides a formulation particularly suited to scalp and hair-bearing skin.

From a commercial perspective, formulation diversification can reduce the risk of the product being confined to a narrow anatomical niche.

Atopic dermatitis becomes another major growth opportunity

Zoryve entered the atopic dermatitis market in July 2024 when the FDA approved the 0.15% cream for mild to moderate disease in adults and children aged 6 years and older.

The approval was supported by the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials, which together enrolled 1,337 patients. At week 4, 32.0% of patients receiving roflumilast in INTEGUMENT-1 and 28.9% in INTEGUMENT-2 achieved the primary vIGA-AD success endpoint, compared with 15.2% and 12.0%, respectively, for vehicle.

The trials also showed improvements in Eczema Area and Severity Index outcomes and itch measures. The results are particularly relevant commercially because atopic dermatitis is a large chronic market with established topical corticosteroids, calcineurin inhibitors, crisaborole, and newer targeted therapies.

Zoryve's positioning is therefore based on occupying the nonsteroidal topical segment while offering a PDE4 mechanism that differs from several other topical therapies.

Pediatric atopic dermatitis expands the franchise further

In October 2025, the FDA approved Zoryve cream 0.05% for mild to moderate atopic dermatitis in children aged 2 to 5 years.

The decision was supported by the INTEGUMENT-PED phase 3 study, which included 652 children. At week 4, 25.4% of patients receiving roflumilast cream achieved vIGA-AD success compared with 10.7% receiving vehicle. EASI-75 and itch outcomes also favored roflumilast.

Longer-term evidence has strengthened the pediatric and chronic-use story. The INTEGUMENT-OLE extension study evaluated roflumilast cream 0.15% in patients aged 6 years and older for up to 52 weeks. Among patients who achieved clear skin and moved to twice-weekly proactive treatment on previously affected areas, clear or almost clear disease was maintained for a median of 281 days. 

These data are relevant to a chronic diseasein which maintaining disease control is as important to treatment strategy as achieving an initial response.

Impact on the Healthcare Industry

More options for chronic inflammatory skin diseases

Zoryve adds a nonsteroidal mechanism to topical treatment pathways for psoriasis, atopic dermatitis, and seborrheic dermatitis.

For clinicians, the significance is less about replacing existing therapies entirely and more about expanding the range of treatments that can be considered according to disease severity, anatomical location, patient age, treatment history, and tolerability.

This is particularly relevant in mild-to-moderate disease, where topical therapy can often remain an important component of care and where avoiding unnecessary escalation to systemic treatment may be clinically and economically attractive.

Formulation can influence adherence.

Topical therapies are often limited not only by pharmacology but also by how easy they are to use. Creams, ointments, solutions, gels, foams, and shampoos have different practical characteristics.

Zoryve's portfolio illustrates how formulation engineering can become a commercial differentiator. The cream targets broad body areas and intertriginous skin, while the foam is designed for scalp and body psoriasis and seborrheic dermatitis.

A product that patients find easier to apply may have an opportunity to improve persistence, although real-world adherence cannot be assumed solely from formulation characteristics. Factors such as insurance coverage, patient preference, disease severity, treatment expectations, and frequency of application also influence utilization.

Pediatric dermatology is becoming an important segment

The 2025 and 2026 pediatric expansions are especially relevant to healthcare delivery.

Zoryve now has FDA-approved cream formulations covering children as young as 2 years for both plaque psoriasis and atopic dermatitis, although the strengths and indications differ by condition. This broadens the potential role of the product in pediatric dermatology and may increase interactions between dermatologists, pediatricians, primary care clinicians, caregivers, and specialty pharmacies.

For healthcare systems, pediatric access also raises practical considerations around formulation, caregiver administration, reimbursement, and long-term treatment expectations.

Market and Business Implications

Zoryve is becoming a franchise rather than a single indication product

The strongest commercial feature of Zoryve is the breadth of its indication-expansion strategy.

Instead of relying on one formulation for one disease, Arcutis has built several products around roflumilast:

• Cream 0.3% for plaque psoriasis.
• Cream 0.15% for atopic dermatitis.
• Cream 0.05% for pediatric atopic dermatitis.
• Foam 0.3% for seborrheic dermatitis.
• Foam 0.3% for scalp and body plaque psoriasis.

This approach allows the company to address multiple dermatology markets while retaining a common mechanism and brand identity.

The financial results demonstrate the effect of that strategy. Zoryve product revenue increased from $166.5 million in 2024 to $372.1 million in 2025. Foam revenue reached $181.9 million in 2025, while cream 0.3% generated $121.0 million and cream 0.15% generated $68.3 million.

In the second quarter of 2026, total Zoryve product revenue reached $129.9 million. Foam accounted for $67.4 million, cream 0.3% for $35.3 million, cream 0.15% for $24.2 million, and cream 0.05% for $2.9 million.

The mix illustrates how recently launched indications can become meaningful contributors while older formulations continue to generate revenue.

Market access is as important as clinical differentiation

A major challenge for branded topical therapies is competition from inexpensive generic treatments.

Topical corticosteroids, calcipotriene, calcineurin inhibitors, antifungals, and other established treatments are already embedded in clinical practice. Payers therefore need evidence that a branded nonsteroidal product provides sufficient clinical or practical value to justify its cost.

Arcutis reported that Medicare access improved beginning in January 2026, although the company noted that approximately one-third of Medicare patients initially had non-preferred access to Zoryve. This demonstrates the continuing role of formulary positioning in determining the commercial value of a prescription medicine.

The company also operates patient-support programs intended to help eligible patients navigate insurance coverage and reduce out-of-pocket costs.

For market analysts, this means Zoryve's prescription trajectory should be assessed alongside payer access, gross-to-net dynamics, formulary positioning, and patient support rather than through demand metrics alone.

The competitive environment is broad.

Zoryve competes in several markets simultaneously.

In plaque psoriasis, competitors include topical corticosteroids, vitamin D analogues, combination products, calcineurin inhibitors for selected sites, tapinarof, and other topical treatments. Systemic and biologic therapies also influence treatment decisions for patients with more extensive or difficult-to-control disease.

In atopic dermatitis, the competitive environment includes topical corticosteroids, tacrolimus, pimecrolimus, crisaborole, topical ruxolitinib, tapinarof, and systemic therapies for appropriate patients.

In seborrheic dermatitis, antifungal shampoos and topical products remain important established treatments, while Zoryve offers a different mechanism through PDE4 inhibition.

This means Arcutis must demonstrate value separately in each disease rather than assuming that success in one indication automatically translates into another.

Geographic expansion creates another opportunity.

Zoryve's commercial potential extends beyond the United States.

In Canada, Health Canada has authorized Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged 6 years and older. Health Canada also authorized the foam 0.3% for plaque psoriasis of the scalp and body in patients aged 12 years and older.

Arcutis has also partnered with Hangzhou Zhongmei Huadong Pharmaceutical, a subsidiary of Huadong Medicine, for development, registration, manufacturing, and commercialization rights covering Greater China and Southeast Asia.

In China, Huadong Medicine submitted a marketing authorization application for roflumilast cream 0.3% for plaque psoriasis in patients aged 6 years and older in 2025. A separate application for the 0.15% cream in atopic dermatitis was also submitted, while the 0.05% pediatric atopic dermatitis application was accepted by China's National Medical Products Administration in February 2026.

These activities show that geographic expansion is becoming part of the longer-term commercial strategy rather than Zoryve being solely a U.S. franchise.

Key Companies and Industry Participants

Arcutis Biotherapeutics

Arcutis is the primary company responsible for developing and commercializing Zoryve. Its business strategy increasingly centers on expanding Zoryve across immuno-dermatology indications while investing in its broader pipeline.

The company reported positive operating cash flow in the fourth quarter of 2025 and maintained positive operating cash flow in the second quarter of 2026. It has also expanded its dermatology sales force and begun building primary-care and pediatric commercial capabilities.

That organizational expansion is important because Zoryve's growing pediatric atopic dermatitis and psoriasis footprint increases the relevance of pediatricians and primary care clinicians alongside dermatologists.

Huadong Medicine

Huadong Medicine is an important international partner for Zoryve. Through its subsidiary Hangzhou Zhongmei Huadong Pharmaceutical, the company holds exclusive rights to develop, register, manufacture, and commercialize roflumilast products across Greater China and several Southeast Asian markets.

The collaboration gives Arcutis access to regulatory and commercial infrastructure in markets where direct commercialization would require substantial local investment.

For Huadong Medicine, roflumilast adds another product to its dermatology and immunology portfolio and provides an opportunity to localize a therapy that has already accumulated substantial clinical and regulatory experience in the United States.

Kowa

Kowa was previously involved in the U.S. commercialization of Zoryve through a promotion agreement. Arcutis and Kowa mutually agreed to terminate that promotion agreement in January 2026.

The change is relevant because it reflects Arcutis's decision to increase direct commercial control as Zoryve expands across multiple indications. A larger internal sales organization can allow more targeted prescriber segmentation and greater coordination across dermatology, primary care, and pediatrics.

Regulatory and research organizations

FDA has been central to the rapid expansion of the Zoryve portfolio, granting multiple approvals and supplemental approvals since 2022.

Health Canada has also authorized several Zoryve formulations and indications. In China, the NMPA is evaluating roflumilast applications from Huadong Medicine.

Clinical researchers and academic dermatology centers have contributed to the DERMIS, STRATUM, ARRECTOR, and INTEGUMENT development programs, generating evidence across different diseases, age groups, and formulations.

Challenges and Limitations

Zoryve's expansion does not remove the challenges associated with topical dermatology markets.

Competition from low-cost established therapies

The largest commercial obstacle is likely the availability of inexpensive generic topical treatments. Corticosteroids and other topical medicines have decades of physician familiarity and broad pharmacy availability.

For Zoryve, a branded prescription price must therefore be justified by its nonsteroidal mechanism, clinical efficacy, formulation characteristics, tolerability, and potential suitability for longer-term management.

Reimbursement can restrict adoption.

Even when a product has favorable clinical evidence, non-preferred formulary placement can create barriers. Patients may face higher out-of-pocket costs or requirements to try lower-cost treatments first.

Arcutis's emphasis on patient access programs and its disclosures concerning Medicare coverage illustrate how market access remains a major component of commercialization.

Safety considerations remain relevant.

Zoryve is generally used topically, but it is not without restrictions.

The U.S. prescribing information contraindicates Zoryve in patients with moderate to severe hepatic impairment, defined as Child-Pugh B or C.

For the foam formulation, the pressurized container contains flammable propellants, and patients are instructed to avoid fire, flame, and smoking during and immediately after application.

The cream and foam formulations also have different adverse-reaction profiles across indications. Consequently, the favorable tolerability of a topical formulation should not be interpreted as an absence of safety considerations.

Clinical evidence is indication-specific

Evidence supporting one Zoryve formulation cannot automatically be transferred to another indication.

For example, data from the STRATUM study support the foam in seborrheic dermatitis, while the INTEGUMENT trials support the 0.15% cream in atopic dermatitis. The ARRECTOR program supports foam use in scalp and body psoriasis.

This distinction becomes particularly important as the portfolio expands. Healthcare professionals and market analysts need to evaluate each formulation and indication according to its own evidence base.

Future Outlook

Zoryve's future is increasingly tied to lifecycle management and expansion beyond its currently approved indications.

Arcutis has identified additional investigational opportunities, including studies of Zoryve foam 0.3% in vitiligo and hidradenitis suppurativa. These programs remain investigational and should not be interpreted as established uses.

The company completed enrollment in its phase 2 vitiligo program in 2026 and expected to disclose topline results and determine whether to advance the program later in the year. It has also been evaluating Zoryve in younger children and submitted an application seeking approval of the 0.05% cream for infants aged 3 to 24 months with mild to moderate atopic dermatitis. FDA accepted that supplemental application and established a February 2027 target action date.

The infant program could be commercially important if approved because treatment options for very young children are a highly scrutinized segment of topical dermatology. At the same time, regulatory review will determine whether the available efficacy, safety, and pharmacokinetic evidence supports the proposed indication.

Arcutis is also developing a broader immuno-dermatology pipeline. Its investigational ARQ-234 program entered first-in-human development in 2026 for atopic dermatitis. This pipeline expansion could eventually reduce reliance on Zoryve alone, although it remains too early to assess the commercial contribution of ARQ-234.

International expansion is another area to monitor. The partnership with Huadong Medicine provides a pathway for roflumilast commercialization in China and Southeast Asia, while Canadian approvals demonstrate the potential for additional markets to adopt the broader franchise.

From a market research perspective, the most important indicators will be prescription persistence, payer access, uptake in newly approved pediatric populations, relative performance against established topical therapies, and whether additional indications can be supported by sufficiently strong clinical evidence.

Conclusion

Zoryve has evolved from a single topical psoriasis product into a multi-indication dermatology franchise built around roflumilast and several formulations. The cream now covers plaque psoriasis in patients as young as 2 years and mild to moderate atopic dermatitis across different pediatric age groups and adults. The foam extends the product into seborrheic dermatitis and scalp and body psoriasis.

The clinical development program has supported this expansion with evidence from DERMIS, STRATUM, ARRECTOR, and INTEGUMENT studies, while longer-term extension data are adding information about sustained treatment and tolerability.

The commercial results show that the strategy is already having a measurable impact. Zoryve generated $372.1 million in net product revenue in 2025, and quarterly revenue reached $129.9 million in the second quarter of 2026. Arcutis has responded by expanding its commercial infrastructure and raising its 2026 sales guidance.

The larger market opportunity comes from addressing several chronic inflammatory skin diseases with nonsteroidal, once-daily topical formulations. Yet Zoryve remains exposed to strong competition from low-cost generic therapies, payer restrictions, established treatment habits, and the need to demonstrate value separately across different indications.

Its future therefore depends on more than additional approvals. Sustained adoption will likely be shaped by reimbursement, real-world treatment persistence, pediatric uptake, international commercialization, and the clinical evidence generated by ongoing lifecycle programs. If the franchise continues to broaden while maintaining access and clinical differentiation, Zoryve could remain an important commercial asset within specialty dermatology and an instructive example of how formulation innovation and indication expansion can reshape the market for topical medicines.

Source References

• U.S. Food and Drug Administration (FDA), ZORYVE (roflumilast) Cream Prescribing Information, updated June 2026.
• U.S. Food and Drug Administration (FDA), ZORYVE (roflumilast) Foam Prescribing Information, updated June 2026.
• U.S. Food and Drug Administration (FDA), ZORYVE Cream 0.3% Approval and Supplemental Approval Materials.
• U.S. Food and Drug Administration (FDA), ZORYVE Foam 0.3% Approval Package, December 2023.
• Arcutis Biotherapeutics, FDA Approves ZORYVE Cream 0.3% for Plaque Psoriasis in Children as Young as Age 2, June 2026.
• Arcutis Biotherapeutics, ZORYVE Cream 0.15% FDA Approval for Atopic Dermatitis, July 2024.
• Arcutis Biotherapeutics, ZORYVE Cream 0.05% FDA Approval for Atopic Dermatitis in Children Ages 2 to 5, October 2025.
• Arcutis Biotherapeutics, ZORYVE Foam 0.3% FDA Approval for Seborrheic Dermatitis, December 2023.
• Arcutis Biotherapeutics, ZORYVE Foam 0.3% FDA Expansion for Scalp and Body Plaque Psoriasis, 2025.
• Arcutis Biotherapeutics, Fourth Quarter and Full Year 2025 Financial Results and Business Update.
• Arcutis Biotherapeutics, Second Quarter 2026 Financial Results and Business Update.
• Arcutis Biotherapeutics, 2026 Strategic Priorities and Anticipated Milestones.
• Simpson EL, et al., Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials, JAMA Dermatology.
• Blauvelt A, et al., Roflumilast Foam 0.3% for Adolescent and Adult Patients With Seborrheic Dermatitis: A Randomized, Double-Blinded, Vehicle-Controlled, Phase 3 Trial, Journal of the American Academy of Dermatology.
• Simpson EL, et al., Roflumilast Cream 0.15% for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials, JAMA Dermatology.
• Eichenfield LF, et al., Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis: INTEGUMENT-PED, Pediatric Dermatology.
• Simpson EL, et al., Long-Term Safety and Efficacy With Roflumilast Cream 0.15% in Patients Aged ≥6 Years With Atopic Dermatitis, Dermatitis.
• PubMed, Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results From the DERMIS Phase III Trials, 2025. 
• Health Canada, Regulatory Decision Summary for Zoryve.
• Health Canada, Notice of Compliance Information for Zoryve Foam 0.3%.
• Huadong Medicine, Roflumilast Cream and Foam Development and Regulatory Updates in China.
• Huadong Medicine, 2025 Annual Report.